We investigated the in vitro postantibiotic effects (PAEs) of the ketolides telithromycin (HMR 3647) and HMR 3004 and analyzed the results using the sigmoid E max model. Mean maximum telithromycin PAEs against erythromycin A-susceptible strains of Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae were 3.7, 8.9, and 9.7 h, respectively, while maximum PAEs for erythromycin A-resistant strains were much shorter. Mean maximum HMR 3004 PAEs were 3.2 to 4.4 h for all species.
Ketolides are a novel class of oral antibiotics. They are semisynthetic macrolides that have good activity against erythromycin A-resistant bacteria, including multidrug-resistant pneumococci, Streptococcus pyogenes, and Staphylococcus aureus (1, 8, 14, 15) . We investigated the in vitro postantibiotic effects (PAEs) of the ketolides telithromycin (HMR 3647) and HMR 3004 against Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus and compared the duration of PAEs and the potency of the agents in producing PAEs against erythromycin A-susceptible and erythromycin A-resistant strains.
(Part of this work was presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstr. F-252] and at the 21st International Congress of Chemotherapy [abstr. P92] .)
The bacteria tested were four strains each of S. pneumoniae and S. pyogenes and five strains of S. aureus, including the reference strains S. aureus ATCC 25923, S. pyogenes ATCC 19615, and S. pneumoniae ATCC 49619. Apart from the ATCC strains, all were recent clinical isolates from the Monash Medical Centre. Two isolates of each species were erythromycin A susceptible, and two or three isolates were erythromycin A resistant. S. aureus strains 3 and 4 were resistant to erythromycin A by an inducible mechanism, detected by a standard disk approximation method (2) ; all other erythromycin A-resistant strains had constitutive erythromycin A resistance.
Telithromycin and HMR 3004 were obtained from Hoechst Marion Roussel, Romainville, France, and were stored and prepared according to the manufacturer's guidelines. Ketolide MICs were determined by the broth macrodilution technique, according to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines (13) . The broths used in experiments were Mueller-Hinton broth (BBL, Becton Dickinson Co., Cockeysville, Md.) for S. aureus, and brain heart infusion broth (Oxoid, Basingstoke, Hampshire, England) for the streptococci. The MICs were determined in ambient air not supplemented with CO 2 , because the presence of 5 to 7% CO 2 has been shown to consistently increase MICs of ketolide for pneumococci by two-to fourfold (14) . MICs of erythromycin A were determined by E-test (4), using a suspension of 0.5 McFarland turbidity plated onto Mueller-Hinton agar (S. aureus) or Mueller-Hinton agar supplemented with 5% blood (streptococci).
The in vitro PAEs were determined by the viable plate count method (7), using Mueller-Hinton broth (S. aureus) or brain heart infusion broth (streptococci). Logarithmic-phase organisms (10 6 CFU) were exposed for 1 h at 37°C to seven concentrations of the ketolide (0.5, 1, 4, 8, 16, 32, and 64 times the MIC). After 1 h, the drug was removed by centrifuging the solution for 10 min at 2,000 ϫ g, decanting the supernatant, and resuspending the organisms in fresh broth prewarmed to 37°C. This washing procedure was performed twice. Washing was selected as the preferred method of drug removal to avoid carryover of the drug from the high concentrations of drug used in the experiments. After drug removal, viable counts were plated hourly until visible regrowth had occurred. The following controls were included for each experiment: (i) a growth control, prepared and treated identically to the test solution but without exposure to antibiotic, and (ii) a residual antibiotic control, to which 1/1,000 of the test antimicrobial concentration was added after centrifugation and washing. The latter tube was included to ensure that, after centrifugation and washing, residual drug in the tubes containing the treated organism did not affect the rate of growth. The PAE was calculated with the standard formula of Craig and Gudmundsson: PAE ϭ T Ϫ C, where T is the time required for the count of CFU in the test culture to increase 1 log 10 above the count observed immediately after drug removal and C is the time required for the count of CFU in an untreated control culture to increase 1 log 10 above the count observed immediately after completion of the same procedure used on the test culture for drug removal (7) .
As the methodology of determining PAE in the laboratory is time-consuming and labor-intensive, we used a mathematical model to predict the PAE for any particular antimicrobial concentration or duration of exposure, based on the data obtained experimentally for the same organism and antimicrobial at other concentrations and durations of exposure. The Hill (sigmoid E max ) equation (9) is a mathematical model that has been used to describe this relationship: PAE ϭ (PAE max ϫ
, where PAE max is the estimated maximum PAE, E 50 is the estimated area under the concentrationtime curve (AUC) of drug exposure at which 50% of the maximum PAE is reached, and n is a constant associated with the steepness of the exposure-response curve. When this equation has been applied to results obtained in some of the original publications on PAE (5, 11) , the correlation between the PAE max estimated using this equation and the experimentally obtained PAE max was very good, with correlation coefficients in the range of 0.96 to 0.995 (16) . This equation has therefore subsequently been used by us to describe the relationship between PAE and AUC of drug exposure (12) . In this study, the sigmoid E max equation was used to mathematically model the exposure-response curve for the ketolides. The parameters PAE max , E 50 , and n for each bacterial strain were estimated with the nonlinear regression module of Systat (version 8.0; SPSS Inc., Chicago, Ill.). MICs were then compared to each of the three parameters by linear regression performed using Systat, with and without the inclusion of a constant.
The PAEs after 1 h of exposure to telithromycin for strains of S. aureus, S. pyogenes, and S. pneumoniae are shown in Table  1 and Fig. 1 and 2 . Maximum PAEs for the streptococci ranged from 3.2 to 10.1 h, while maximum PAEs for S. aureus were shorter than the streptococcal PAEs, ranging from 3.5 to 4.3 h. Table 1 also shows the correlation between the PAEs determined experimentally and those estimated using the Hill (sigmoid E max ) equation, with corrected r 2 ranging from 0.857 to 0.978.
PAEs after 1 h of exposure to HMR 3004 are shown in Table  2 and Fig. 3 and 4 . Maximum PAEs for S. aureus, S. pyogenes, and S. pneumoniae ranged from 2.7 to 4.9 h. PAEs against streptococci were much shorter than those of telithromycin, but there was little difference between the drugs in duration of PAEs against staphylococci. Once again, there was good correlation between actual PAEs and PAEs estimated using the mathematical model, with corrected r 2 ranging from 0.931 to 0.995.
A comparison of MIC, PAE max , and E 50 between erythromycin A-susceptible and -resistant strains is shown in Table 3 . For S. aureus, the effects of resistance were similar for both drugs, with a negligible effect on MIC or PAE max but a two-to fourfold increase in E 50 . For S. pyogenes and telithromycin, although the MICs for resistant strains were increased more than 20-fold, PAE max was reduced only about twofold, and E 50 d To achieve a satisfactory curve fit, PAE max was fixed at the maximum value observed experimentally. e These strains also had reduced susceptibility to penicillin.
was increased only about fourfold. In contrast, with HMR 3004, MICs for resistant strains increased about sixfold but there was no effect on either PAE max or E 50 . For S. pneumoniae, the only observable effect of erythromycin A resistance was an eightfold increase in the MIC of telithromycin; the PAE parameters remained unaffected.
In a previous study, we demonstrated a significant relationship between E 50 and the MIC of imipenem (12) . However, resistant strains were not included. For the ketolides, when examined by linear regression, correlation between MIC and PAE max , n, and E 50 in particular was poor except for HMR 3004 when regression was performed through the origin (without a constant), yielding a moderate correlation with all three parameters. In many instances regression detected outliers. Both of these findings, and an examination of E 50 /MIC ratios for erythromycin A-susceptible and -resistant strains, as shown in Table 3 , suggest that the MIC changes observed with erythromycin-resistant strains do not necessarily predict changes in postantibiotic growth suppression. This may relate to differences in resistance mechanisms within and between species.
Others have previously examined postantibiotic growth suppression of telithromycin, but in less detail. One study examining PAEs of HMR 3647 (now named telithromycin) found in vitro PAEs of 3.7 to 8. The duration of PAEs in our study generally peaked with concentrations of 32 to 64 times the MIC, concentrations which, according to the pharmacokinetic data, can readily be achieved in humans. Other human pharmacokinetic studies show that levels of telithromycin are 10-to 100-fold higher in lung than in plasma (C. Serleys, C. Cantalloube, P. Soler, F. Lemaitre, H. P. Gia, F. Brunner, and A. Andremont, Abstr. 21st Int. Congr. Chemother., abstr. P78, 1999) and that intracellular levels of the drug are 350 times higher in polymorphonuclear leukocytes than in the extracellular space (17) . Thus, the concentrations of telithromycin we used in vitro are readily achievable both in human plasma and in tissues, and results obtained are likely to be clinically relevant.
Studies performed in the murine neutropenic thigh-infection model have shown that the 24 h AUC/MIC ratio is the pharmacokinetic/pharmacodynamic parameter that best correlates with the activity of telithromycin against S. pneumoniae and that this parameter is a much better predictor of efficacy than time above MIC (O. Vesga, W. A. Craig, and C. Bonnat, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-255, 1997). This study did not measure the in vivo PAE, but if the prolonged PAE of telithromycin against streptococci is present in vivo, it may help explain this finding. Similar studies do not appear to have been performed for HMR 3004.
Although the presence or absence of in vivo PAE is usually predicted by in vitro studies (6) , in vitro studies such as ours have several limitations, including the exposure of bacteria to fixed concentrations of drug, and the immediate rather than gradual removal of drug, neither of which occur in a living system. Our results should therefore be confirmed in animal models, as host defense mechanisms, concentrations of drug within the cell, tissue binding of drug, and sub-MIC effects may be important. Also, we have not tested durations of exposure to drug other than 1 h. In vivo, the duration of exposure is likely to be significantly longer than this. However, previous studies have shown that the duration of the PAE is strongly correlated with the AUC of the drug, the product of concentration of drug versus duration of exposure to drug (5, 10, 12) . Therefore, for example, doubling the concentration of the drug 
